CRM197-induced Blood-brain Barrier Permeability Increase is Mediated by Upregulation of Caveolin-1 Protein

Overview

Journal J Mol Neurosci

Specialties Molecular Biology
Neurology

Date 2010 Nov 17

PMID 21080104

Citations 15

Authors

Ping Wang

Yunhui Liu

Xiuli Shang

Yixue Xue

Affiliations

Soon will be listed here.

Abstract

Cross-reacting material 197 (CRM197), a non-toxin mutant of diphtheria toxin, could act as a diphtheria toxin receptor-specific carrier protein for the targeted delivery of macromolecular substances across the blood-brain barrier (BBB) in vitro. This study was performed to investigate the effects and mechanisms of CRM197 on the permeability of BBB in guinea pigs. Data from the Evans blue extravasation showed that the BBB permeability significantly increased after CRM197 injection in a dose-dependent manner. Transmission electron microscopy indicated CRM197 could induce increased pinocytotic vesicles and vacuoles in brain microvascular endothelial cells. Immunohistochemistry and western blot assay revealed that CRM197 enhanced caveolin-1 protein expression in brain microvessels. The caveolin-1 protein in the membrane fraction of microvessels began to upregulate at 5 min and reached the peak at 10 min after CRM197 treatment, associated by diminished expression of several tight junction-associated proteins ZO-1, occludin, and claudin-5. Thus, our results indicate that the in vivo targeting CRM197 leads to increased BBB permeability via upregulation of caveolin-1 protein, increased pinocytotic vesicles, and redistribution of tight junction-associated proteins in brain microvessels. CRM197 may have a potential application for targeted drug delivery across the BBB.

Citing Articles

Current Update on Transcellular Brain Drug Delivery.

Pawar B, Vasdev N, Gupta T, Mhatre M, More A, Anup N Pharmaceutics. 2022; 14(12).

PMID: 36559214 PMC: 9786068. DOI: 10.3390/pharmaceutics14122719.

A Historical Review of Brain Drug Delivery.

Pardridge W Pharmaceutics. 2022; 14(6).

PMID: 35745855 PMC: 9229021. DOI: 10.3390/pharmaceutics14061283.

Current Chemical, Biological, and Physiological Views in the Development of Successful Brain-Targeted Pharmaceutics.

Markowicz-Piasecka M, Markiewicz A, Darlak P, Sikora J, Adla S, Bagina S Neurotherapeutics. 2022; 19(3):942-976.

PMID: 35391662 PMC: 9294128. DOI: 10.1007/s13311-022-01228-5.

Brain Delivery of Nanomedicines: Trojan Horse Liposomes for Plasmid DNA Gene Therapy of the Brain.

Pardridge W Front Med Technol. 2022; 2:602236.

PMID: 35047884 PMC: 8757841. DOI: 10.3389/fmedt.2020.602236.

Protease Responsive Nanogels for Transcytosis across the Blood-Brain Barrier and Intracellular Delivery of Radiopharmaceuticals to Brain Tumor Cells.

Singh S, Drude N, Blank L, Desai P, Konigs H, Rutten S Adv Healthc Mater. 2021; 10(20):e2100812.

PMID: 34490744 PMC: 11468667. DOI: 10.1002/adhm.202100812.

References

Zhang S, Liu Y, Zhao Z, Xue Y . Effects of green tea polyphenols on caveolin-1 of microvessel fragments in rats with cerebral ischemia. Neurol Res. 2010; 32(9):963-70. DOI: 10.1179/016164110X12700393823570. View

Chang T, Neville Jr D . Demonstration of diphtheria toxin receptors on surface membranes from both toxin-sensitive and toxin-resistant species. J Biol Chem. 1978; 253(19):6866-71. View

Lajoie P, Nabi I . Regulation of raft-dependent endocytosis. J Cell Mol Med. 2007; 11(4):644-53. PMC: 3823247. DOI: 10.1111/j.1582-4934.2007.00083.x. View

Frank P, Pavlides S, Lisanti M . Caveolae and transcytosis in endothelial cells: role in atherosclerosis. Cell Tissue Res. 2008; 335(1):41-7. DOI: 10.1007/s00441-008-0659-8. View

Anderson R, Kamen B, Rothberg K, Lacey S . Potocytosis: sequestration and transport of small molecules by caveolae. Science. 1992; 255(5043):410-1. DOI: 10.1126/science.1310359. View

Tanaka N, Sasahara M, Ohno M, Higashiyama S, Hayase Y, Shimada M . Heparin-binding epidermal growth factor-like growth factor mRNA expression in neonatal rat brain with hypoxic/ischemic injury. Brain Res. 1999; 827(1-2):130-8. DOI: 10.1016/s0006-8993(99)01319-0. View

Michel C, Neal C . Openings through endothelial cells associated with increased microvascular permeability. Microcirculation. 1999; 6(1):45-54. View

Tagawa A, Mezzacasa A, Hayer A, Longatti A, Pelkmans L, Helenius A . Assembly and trafficking of caveolar domains in the cell: caveolae as stable, cargo-triggered, vesicular transporters. J Cell Biol. 2005; 170(5):769-79. PMC: 2171342. DOI: 10.1083/jcb.200506103. View

Bathori G, Cervenak L, Karadi I . Caveolae--an alternative endocytotic pathway for targeted drug delivery. Crit Rev Ther Drug Carrier Syst. 2004; 21(2):67-95. DOI: 10.1615/critrevtherdrugcarriersyst.v21.i2.10. View

10.

Genedani S, Guidolin D, Leo G, Filaferro M, Torvinen M, Woods A . Computer-assisted image analysis of caveolin-1 involvement in the internalization process of adenosine A2A-dopamine D2 receptor heterodimers. J Mol Neurosci. 2005; 26(2-3):177-84. DOI: 10.1385/JMN:26:2-3:177. View

11.

Feng D, Nagy J, Hipp J, Dvorak H, Dvorak A . Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin. J Exp Med. 1996; 183(5):1981-6. PMC: 2192559. DOI: 10.1084/jem.183.5.1981. View

12.

Mishima K, Higashiyama S, Asai A, Yamaoka K, Nagashima Y, Taniguchi N . Heparin-binding epidermal growth factor-like growth factor stimulates mitogenic signaling and is highly expressed in human malignant gliomas. Acta Neuropathol. 1998; 96(4):322-8. DOI: 10.1007/s004010050901. View

13.

Xia C, Zhang Z, Xue Y, Wang P, Liu Y . Mechanisms of the increase in the permeability of the blood-tumor barrier obtained by combining low-frequency ultrasound irradiation with small-dose bradykinin. J Neurooncol. 2009; 94(1):41-50. DOI: 10.1007/s11060-009-9812-9. View

14.

Song L, Pachter J . Culture of murine brain microvascular endothelial cells that maintain expression and cytoskeletal association of tight junction-associated proteins. In Vitro Cell Dev Biol Anim. 2003; 39(7):313-20. DOI: 10.1290/1543-706X(2003)039<0313:COMBME>2.0.CO;2. View

15.

Gaillard P, Visser C, de Boer A . Targeted delivery across the blood-brain barrier. Expert Opin Drug Deliv. 2005; 2(2):299-309. DOI: 10.1517/17425247.2.2.299. View

16.

Sigurdardottir S, Davidsdottir K, Arason V, Jonsdottir O, Laudat F, Gruber W . Safety and immunogenicity of CRM197-conjugated pneumococcal-meningococcal C combination vaccine (9vPnC-MnCC) whether given in two or three primary doses. Vaccine. 2008; 26(33):4178-86. DOI: 10.1016/j.vaccine.2008.05.072. View

17.

Predescu S, Predescu D, Malik A . Molecular determinants of endothelial transcytosis and their role in endothelial permeability. Am J Physiol Lung Cell Mol Physiol. 2007; 293(4):L823-42. DOI: 10.1152/ajplung.00436.2006. View

18.

Yagi H, Yotsumoto F, Sonoda K, Kuroki M, Mekada E, Miyamoto S . Synergistic anti-tumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer. Int J Cancer. 2008; 124(6):1429-39. DOI: 10.1002/ijc.24031. View

19.

Drewes L . Molecular architecture of the brain microvasculature: perspective on blood-brain transport. J Mol Neurosci. 2001; 16(2-3):93-8; discussion 151-7. DOI: 10.1385/JMN:16:2-3:93. View

20.

Mitamura T, Higashiyama S, Taniguchi N, Klagsbrun M, Mekada E . Diphtheria toxin binds to the epidermal growth factor (EGF)-like domain of human heparin-binding EGF-like growth factor/diphtheria toxin receptor and inhibits specifically its mitogenic activity. J Biol Chem. 1995; 270(3):1015-9. DOI: 10.1074/jbc.270.3.1015. View